Biogen Inc. in 2 stories
The narratives BIIB currently appears in, with its side and exposure in each.
Bull side
0 storiesNo bull-side stories for BIIB yet.
Bear side
2 stories- America Imports the World's Drug Prices
BIIB in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Biogen relies on premium-priced patented neurology medicines whose lifetime economics could weaken if US reimbursement is benchmarked against lower overseas prices.
- The Patent Cliff Sparks a Biotech Land Grab
BIIB in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Erosion in mature neurological franchises and uneven internal pipeline execution leave Biogen under pressure to license or acquire new growth assets.